These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32892996)

  • 1. Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
    Oyedeji CI; Crawford RD; Shah N
    J Natl Med Assoc; 2021 Apr; 113(2):170-176. PubMed ID: 32892996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
    Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
    Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
    Taher AT; Origa R; Perrotta S; Kouraklis A; Ruffo GB; Kattamis A; Goh AS; Huang V; Zia A; Herranz RM; Porter JB
    Health Qual Life Outcomes; 2018 Nov; 16(1):216. PubMed ID: 30453981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in iron chelation therapy: transitioning to a new oral formulation.
    Shah NR
    Drugs Context; 2017; 6():212502. PubMed ID: 28706555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia.
    Viprakasit V; Hamdy MM; Hassab HMA; Sherief LM; Al-Bagshi M; Khattab M; Chuncharunee S; Dung PC; Küpesiz A; Shekhawat A; Sonawane Y; Perez LT; Slader C; Taher AT
    Ann Hematol; 2023 Aug; 102(8):2039-2049. PubMed ID: 37227493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
    Taher AT; Origa R; Perrotta S; Kourakli A; Ruffo GB; Kattamis A; Goh AS; Cortoos A; Huang V; Weill M; Merino Herranz R; Porter JB
    Am J Hematol; 2017 May; 92(5):420-428. PubMed ID: 28142202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning Patients With Iron Overload From Exjade to Jadenu.
    Tinsley SM; Hoehner-Cooper CM
    J Infus Nurs; 2018; 41(3):171-175. PubMed ID: 29659464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
    Taher AT; Wali Y; Cruz MC; Charoenkwan P; Aydinok Y; Werner O; Govindaraju S; Romen F; Viprakasit V
    Haematologica; 2024 May; 109(5):1413-1425. PubMed ID: 37855069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
    Piolatto A; Berchialla P; Allegra S; De Francia S; Ferrero GB; Piga A; Longo F
    Sci Rep; 2021 Jun; 11(1):12581. PubMed ID: 34131221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jadenu
    Yassin MA; Soliman AT; De Sanctis V; Hussein RM; Al-Okka R; Kassem N; Ghasoub R; Basha A; Nashwan AJ; Adel AM
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018064. PubMed ID: 30416696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
    Kattamis A; Aydinok Y; Taher A
    Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions.
    Chalmers AW; Shammo JM
    Ther Clin Risk Manag; 2016; 12():201-8. PubMed ID: 26929633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
    Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
    J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
    Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR; Delhikumar CG; Ram Kumar G
    Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
    Ballas SK; Zeidan AM; Duong VH; DeVeaux M; Heeney MM
    Am J Hematol; 2018 Jul; 93(7):943-952. PubMed ID: 29635754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.